Palvella Therapeutics (PVLA) Current Assets (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Current Assets of $263.2 million for Q1 2026, up 231.36% year-over-year from $79.4 million in Q1 2025, and up 346.25% quarter-over-quarter from $59.0 million in Q4 2025.
Palvella Therapeutics (PVLA) Current Assets (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Current Assets for 14 consecutive years, with $263.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 231.36% year-over-year to $263.2 million; the TTM figure through Mar 2026 stood at $263.2 million (up 231.36% YoY), while the FY2025 annual figure was $59.0 million, down 33.15% from the prior year.
- Current Assets grew to $263.2 million in Q1 2026 per PVLA's latest filing, from $59.0 million in the prior quarter.
- Across five years, Current Assets topped out at $263.2 million in Q1 2026 and bottomed at $7.5 million in Q4 2023.
- Historically, Current Assets has averaged $84.2 million across 5 years, with a median of $73.6 million in 2022.
- Annual changes were most pronounced in 2023 — Current Assets tumbled 89.72% — and 2024, when it surged 1068.97%.
- Palvella Therapeutics' Current Assets stood at $73.4 million in 2022, then sank by 89.72% to $7.5 million in 2023, then soared by 1068.97% to $88.2 million in 2024, then sank by 33.15% to $59.0 million in 2025, then jumped by 346.25% to $263.2 million in 2026.
- Business Quant data shows PVLA's Current Assets at $263.2 million in Q1 2026, $59.0 million in Q4 2025, and $66.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 253.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253.03 Mn |
| Mar 31, 2026 | 263.23 Mn |
| Dec 31, 2025 | 58.99 Mn |
| Sep 30, 2025 | 66.94 Mn |
| Jun 30, 2025 | 73.75 Mn |
| Mar 31, 2025 | 79.44 Mn |
| Dec 31, 2024 | 88.23 Mn |
| Dec 31, 2023 | 7.55 Mn |
| Sep 30, 2023 | 59.09 Mn |
| Jun 30, 2023 | 66.47 Mn |
| Mar 31, 2023 | 60.51 Mn |
| Dec 31, 2022 | 73.42 Mn |
| Sep 30, 2022 | 78.56 Mn |
| Jun 30, 2022 | 90.90 Mn |
| Mar 31, 2022 | 111.75 Mn |
| Dec 31, 2021 | 127.63 Mn |
| Sep 30, 2021 | 137.65 Mn |
| Jun 30, 2021 | 127.67 Mn |
| Mar 31, 2021 | 88.27 Mn |
| Dec 31, 2020 | 75.72 Mn |